ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Pretreatment Extent of Disease (PRETEXT) in the risk stratification schemes of the major hepatoblastoma study groups

Pretreatment Extent of Disease (PRETEXT) in the risk stratification schemes of the major hepatoblastoma study groups
  COG SIOPEL GPOH JPLT
Very low risk PRETEXT I or II, pure fetal histology, and primary resection      
Low risk/standard risk PRETEXT I or II, any histology, and primary resection PRETEXT I, II, and III PRETEXT I, II, and III PRETEXT I, II, and III
Intermediate risk PRETEXT II, III, or IV; unresectable at diagnosis V+, P+, E+SCU     PRETEXT IV any, PRETEXT with rupture, N1, P2, P2a,V3, and V3a multifocal
High risk Any PRETEXT M+AFP level <100 ng/mL Any PRETEXT V+, P+, E+, M+SCU, AFP level <100 ng/mL, tumor rupture Any PRETEXT V+, P+, E+, M+multifocal Any PRETEXT M1, N2 AFP level <100 ng/mL
COG: Children's Oncology Group; SIOPEL: International Childhood Liver Tumors Strategy Group; GPOH: German Society for Pediatric Oncology and Hematology; JPLT: Japanese Study Group for Pediatric Liver Tumors; AFP: alpha-fetoprotein.
From: Meyers RL, Tiao G, de Ville de Goyet J, et al. Hepatoblastoma state of the art: pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation. Curr Opin Pediatr 2014; 26:29. DOI: 10.1097/MOP.0000000000000042. Copyright © 2014. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.
Graphic 120948 Version 3.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟